Topcul M, Cetin I, Ozlem Kolusayin Ozar M
Istanbul University, Faculty of Science, Department of Biology, Istanbul, Turkey.
J BUON. 2013 Oct-Dec;18(4):874-8.
In this study, the antiproliferative effects of the aromatase inhibitor anastrozole (arimidex®) was evaluated on estrogen receptor (ER) positive FM3A cell line originated from C3H mouse mammary carcinoma.
For this purpose cell kinetic parameters including viability analysis, mitotic index and labelling index were used. Three different doses of anostrozole (D1= 0.01 μM, D2= 0.1μM, D3= 1μM) were applied to cells for 24 h to determine the most effective dose. A dose of 1μM dose was determined as the most effective and this was used in all subsequent applications for 0-72 h.
The results showed that there was a significant decrease in viability, mitotic index and labelling index for all experimental groups. The differences between control and all experimental groups were statistically significant (p<0.01) for all applications.
Anastrozole offers a promising treatment modality in estrogen sensitive breast cancer.
